A Biology Modality MCP review of CLDN9 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.

A Biology Modality MCP review of CLDN7 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.

A Biology Modality MCP review of CLDN8 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.

A Biology Modality MCP review of CLDN1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.

A Biology Modality MCP review of CLDN2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.

A Biology Modality MCP review of CLDN5 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.

A Biology Modality MCP review of BACE2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.

A Biology Modality MCP review of BACE1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.

A Biology Modality MCP review of CCL11 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.

A Biology Modality MCP review of ALK sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.

A Biology Modality MCP review of ADGRF5 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.

NCT07517419 clinical trial report covering Doxorubicin Hydrochloride, Phase 2, endpoints, sponsor, geography, readout timing and development white space.